Today’s news reports cover items on:
- Extent and number of biopsy cores and eligibility for active surveillance
- Intermittent vs. complete androgen deprivation
- Hormone therapy and risk for cardiovascular disease and death
- Surrogate markets for disease progression in men with CRPC … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, androgen deprivation, biopsy, cardiovasular, castration-resistant prostate cancer, complete, CRPC, hormone therapy, intermittent, marker, protocol, side effects, surrogate | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 